• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BioHarvest Launches Informed Sport-Certified VINIA DailyChews 2X Formula for Athletes and People with Active Lifestyles

    6/4/25 7:00:00 AM ET
    $BHST
    Get the next $BHST alert in real time by email

    Rehovot, Israel--(Newsfile Corp. - June 4, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced the launch of VINIA® DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. VINIA® DailyChews 2X Formula are now available for purchase in a 30-count pack on VINIA.com.

    Formulated with a double dose of BioHarvest's proprietary red grape cell composition, VINIA® DailyChews 2X Formula are officially Informed Sport-certified, underscoring the Company's commitment to cleaner, safer, and effective performance nutrition. The globally recognized certification ensures every batch is tested for banned substances, making it a trusted choice for professional athletes, military personnel, and fitness enthusiasts alike.

    Each individually packaged VINIA® DailyChews 2X Formula contains 800mg of VINIA® and 12 mg of Piceid resveratrol, which has been clinically shown to increase arterial dilation. This arterial dilation improves blood flow, delivering more oxygen and nutrients to the body's muscles, tissues, and cells, improving physical energy and mental alertness.*

    "Our customers lead dynamic, high-performance lives, and they deserve a product that meets the highest standards for efficacy, safety and ease of use," said Ilan Sobel, CEO of BioHarvest. "The launch of VINIA® DailyChews 2x Formula - with Informed Sport certification - marks a major milestone as we expand into the athlete and fitness enthusiast segment of the multi-billion-dollar nutraceuticals market and address a younger consumer base. In addition, our new international ecommerce platform enables global orders, so that customers in countries which allow importation of supplements, such as the UK and Australia, can now have VINIA® products delivered directly to their doorstep with local tax and import fee calculations handled automatically on the backend.

    "This launch complements our growing VINIA® Inside portfolio, which includes the core capsule business and hot beverage line of teas and coffees, reflecting our broader strategy to meet increasing global demand for plant-based, science-backed solutions," concluded Sobel.

    *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

    About Informed Sport

    Informed Sport is the world's leading testing and certification program for brands producing sports and nutritional supplements. Designed for elite sport, it protects athletes from inadvertent doping caused by supplements contaminated with banned substances. As such, it is recognised by sporting and governing bodies, anti-doping bodies and nutrition industry organisations, and the armed and special forces. https://sport.wetestyoutrust.com/

    About BioHarvest Sciences Inc.

    BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

    Forward-Looking Statements

    Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

    BioHarvest Corporate Contact:
    Dave Ryan, VP Investor Relations
    +1 (604) 622-1186
    [email protected]

    Investor Relations Contact:
    Lucas A. Zimmerman
    Managing Director
    MZ Group - MZ North America
    +1 (949) 259-4987
    [email protected]

    Corporate Logo

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254440

    Get the next $BHST alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHST

    DatePrice TargetRatingAnalyst
    5/5/2025$15.00Buy
    Craig Hallum
    12/18/2024$12.00Buy
    Maxim Group
    More analyst ratings

    $BHST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on BioHarvest Sciences with a new price target

    Craig Hallum initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $15.00

    5/5/25 8:30:45 AM ET
    $BHST

    Maxim Group initiated coverage on BioHarvest Sciences with a new price target

    Maxim Group initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $12.00

    12/18/24 8:10:03 AM ET
    $BHST

    $BHST
    SEC Filings

    View All

    SEC Form 424B7 filed by BioHarvest Sciences Inc.

    424B7 - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

    10/15/25 5:17:08 PM ET
    $BHST

    SEC Form 424B7 filed by BioHarvest Sciences Inc.

    424B7 - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

    9/24/25 4:38:27 PM ET
    $BHST

    SEC Form 6-K filed by BioHarvest Sciences Inc.

    6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

    9/23/25 3:41:41 PM ET
    $BHST

    $BHST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioHarvest Sciences Strengthens Balance Sheet by $14.7 Million with Injection of $10.9 Million Gross Proceeds and Additional $3.8 Million in Debt Reduction

    Rehovot, Israel--(Newsfile Corp. - September 22, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced the successful completion of a series of accelerated warrant exercises and conversions of debt to equity, which fortifies the Company's balance sheet with an additional $10.9 Million in gross proceeds and a concurrent $3.8 Million reduction in total debt.The following are the transactions which were executed subsequent to the Company's published Q2 2025 Financial Statements:Successfully raised $5.8 Million in incremental cash through the exercising of 898,277 w

    9/22/25 6:32:00 AM ET
    $BHST

    BioHarvest Sciences Announces Breakthrough in Botanical Synthesis Capabilities with Plant-Based Exosome Production at Scale

    Exosomes Produced in the Liquid Media of the BioHarvest Unique Large-Scale Bioreactors Add Potential New Revenue Stream from Products and CDMO OpportunitiesRehovot, Israel--(Newsfile Corp. - September 10, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it has successfully produced, at scale, plant-based exosomes in its bioreactor media, marking a significant advancement in the Company's proprietary Botanical Synthesis platform and in its ability to generate new revenue streams.Exosomes are nano-sized extracellular vesicles naturally secreted by plant cel

    9/10/25 7:00:00 AM ET
    $BHST

    BioHarvest Sciences to Host a Virtual Investor Webinar on September 10, 2025 at 1:00 PM ET

    Rehovot, Israel--(Newsfile Corp. - September 2, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management will host a Virtual Investor Webinar on Wednesday, September 10, 2025 at 1:00 p.m. Eastern time.CEO Ilan Sobel will host the virtual investor webinar to provide a corporate update on new capability-building initiatives, the Company's 'Big Bets' for 2H 2025, and will conclude with a question-and-answer session from dial-in participants. To attend, please reference the access information below: Virtual Investor WebinarDate: Wednesday, September 10, 20

    9/2/25 8:30:00 AM ET
    $BHST

    $BHST
    Leadership Updates

    Live Leadership Updates

    View All

    BioHarvest Announces Appointment of Sharon Malka to Board of Directors

    Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the BoardVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 22, 2025) - BioHarvest Sciences Inc., (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest. The appointment is effective immediately."We are very pleased to announce the addition of Mr. Malka to the BioHarvest Board of Directors," said Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division

    1/22/25 8:30:00 AM ET
    $BHST

    $BHST
    Financials

    Live finance-specific insights

    View All

    BioHarvest Sciences Reports Second Quarter 2025 Financial Results

    Robust 41% Year-Over-Year Revenue Growth, Driven by Strong Core Capsule and New Product SalesRehovot, Israel--(Newsfile Corp. - August 11, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the second quarter ended June 30, 2025.Second Quarter 2025 HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the second quarter of 2025 increased 41% year-over-year to $8.5 million, in line with management guidance, with gross margins of 60% expanding by 800 basis points y

    8/11/25 7:30:00 AM ET
    $BHST

    BioHarvest Sciences to Host Second Quarter 2025 Earnings Call on August 11 at 8:00 a.m. Eastern Time

    Rehovot, Israel--(Newsfile Corp. - August 4, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the second quarter ended June 30, 2025 before market open on Monday, August 11, 2025.Management will host an investor conference call and webcast at 8:00 a.m. Eastern time on Monday, August 11, 2025 to discuss the Company's second quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information:Second Q

    8/4/25 8:30:00 AM ET
    $BHST

    BioHarvest Sciences Reports First Quarter 2025 Financial Results

    First Quarter Revenues Grew 47% to $7.9 Million, Exceeding Management GuidanceRehovot, Israel--(Newsfile Corp. - May 15, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the first quarter ended March 31, 2025.First Quarter & Subsequent 2025 Operational HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the first quarter of 2025 increased 47% year-over-year to $7.9 million, exceeding management guidance, with gross margins expanding by 227 basis points to 58.

    5/15/25 4:05:00 PM ET
    $BHST